Astellas Licenses Regional Rights to Optimer Pharmaceuticals’ Antibiotic for Clostridium Difficile Infection
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 20 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1435 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Optimer Pharmaceuticals has partnered with Astellas Pharma in a regional licensing deal worth US$224 M to develop and commercialise its experimental antibiotic, fidaxomicin (OPT-80), for Clostridium difficile infection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS